1. |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
|
2. |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5):E359-E386.
|
3. |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
|
4. |
Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol, 2006, 12(1):17-20.
|
5. |
de Andres-Aguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis. Curr Opin Hematol, 2012, 19(4):268-272.
|
6. |
Glazer RI, Wang XY, Yuan H, et al. Musashi1:a stem cell marker no longer in search of a function. Cell Cycle, 2008, 7(17):2635-2639.
|
7. |
Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med, 2010, 16(8):903-908.
|
8. |
Park SM, Gonen M, Vu L, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest, 2015, 125(3):1286-1298.
|
9. |
Mu Q, Wang Y, Chen B, et al. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia. Leuk Res, 2013, 37(8):922-927.
|
10. |
Okano H, Kawahara H, Toriya M, et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res, 2005, 306(2):349-356.
|
11. |
Toda M, Iizuka Y, Yu W, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia, 2001, 34(1):1-7.
|
12. |
高志刚, 郭克建, 宋少伟. MSI2在胰腺癌中的表达及其临床意义.中华胰腺病杂志, 2014, 14(6):392-395.
|
13. |
何璐, 周新科, 洪健.肝细胞癌中Musashi2的表达及意义.广东医学, 2013, 34(20):3152-3154.
|
14. |
Aly RM, Ghazy HF. Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia. Int J Lab Hematol, 2015, 37(2):272-278.
|
15. |
Kaeda J, Ringel F, Oberender C, et al. Up-regulated MSI2 is associ-ated with more aggressive chronic myeloid leukemia. Leuk Lymphoma, 2015, 56(7):2105-2113.
|
16. |
Han Y, Ye A, Zhang Y, et al. Musashi-2 silencing exerts potent acti-vity against acute myeloid leukemia and enhances chemosensitivity to daunorubicin. PLoS One, 2015, 10(8):e0136484.
|
17. |
Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun, 2015, 6:6517.
|
18. |
王娅菲, 林中, 卢青, 等. musashi-2、CD133在结肠腺癌中的表达.天津医药, 2013, 41(12):1153-1155.
|
19. |
Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells:promise of targeted therapy. Gastroenterology, 2010, 138(6):2151-2162.
|
20. |
莫碧文, 李劳冬, 于会娜, 等. Musashi2在肺癌中的表达及其临床意义.安徽医科大学学报, 2013, 48(12):1480-1483.
|
21. |
Moreira AL, Gonen M, Rekhtman N, et al. Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol, 2010, 23(6):889-895.
|
22. |
MacNicol AM, Wilczynska A, MacNicol MC. Function and regula-tion of the mammalian Musashi mRNA translational regulator. Biochem Soc Trans, 2008, 36(Pt 3):528-530.
|
23. |
He L, Zhou X, Qu C, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med, 2014, 18(1):49-58.
|
24. |
Wang MH, Qin SY, Zhang SG, et al. Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/beta-catenin pathway. Am J Cancer Res, 2015, 5(3):1089-1100.
|
25. |
Cox JL, Wilder PJ, Gilmore JM, et al. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One, 2013, 8(5):e62857.
|
26. |
Emadi-Baygi M, Nikpour P, Mohammad-Hashem F, et al. MSI2 expression is decreased in gradeⅡof gastric carcinoma. Pathol Res Pract, 2013, 209(11):689-691.
|